Celleo has begun emerging from the shadows of biotech stealth mode.
Celleo was founded in early-2022 by David Kneen, Jon Ellis and Mark Rob to develop and supply intelligent production systems for the manufacture of Cell & Gene Therapies at clinical through commercial scales. Celleo marries deep biological and industry experience with modern manufacturing approaches to bridge the production gap for tomorrow’s advanced therapeutics.
“The extraordinary potential of Cell & Gene Therapies to deliver population-level health outcomes won’t be realised without intelligent production systems.” remarked CEO and Head of Commercial David Kneen. “The transition from laboratory to commercially-relevant therapeutic needs to build-in the intent to reach broader patient populations whilst achieving credible return on investment.” David previously led a renowned global business unit delivering custom manufacturing solutions for Cell & Gene Therapies to the world’s leading biotherapeutics players.
While in stealth mode, Celleo has been developing, testing and refining production systems for Cell & Gene Therapy manufacture, engaging privately with some of the world’s leading biotherapeutics developers, manufacturers and CDMOs. Celleo completed its initial client delivery of a clinical-scale production system in Q4, 2022, with tech transfer to the client’s CDMO scheduled in 2023 ahead of therapeutic manufacture for FIH use.
“Commercial cell therapy manufacturing today remains in its infancy, typically extrapolating laboratory tools and techniques, or force-fitting critical processes into systems with limited functionality.” commented CSO and Head of Biology Jon Ellis. “Today’s pathfinding therapies have tolerated that compromise – it’s time for the next chapter.” Jon previously managed a GMP cord blood and bone marrow transplantation laboratory before embarking on the development of next-generation therapeutic production systems.
Celleo envisions a future industry where myriad therapeutic and production modalities thrive, each optimized in parallel for process effectiveness and commercial outcomes. The company believes that therapeutic owners should be empowered to configure production systems for their specific application from a diverse toolkit of standardized, interoperable process elements, each rigorously demonstrated.
“Sophisticated simplicity is a hallmark of great design, and nowhere is this more critical than in the industrial-scale GMP production of Cell & Gene Therapies.” explained CTO and Head of Product Development Mark Rob. “Our pipeline of platform technologies encapsulate critical cell-manufacturing operations, yet are engineered to ensure the rigorous process control required seems effortless.” Mark has twice led teams to receive the prestigious Australian Design Award for biomedical manufacturing systems, a legacy testament to Mark’s foundations in high-precision automotive drivetrain development prior to his 15 years in biotech.
Celleo is currently working behind the scenes with selected global partners to mature a portfolio of production systems with broad application for the manufacture of Cell & Gene Therapies, and invites parties interested in collaborating or wishing to stay informed of progress to connect with us here.